Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA internal medicine"
DOI: 10.1001/jamainternmed.2022.6299
Abstract: This cross-sectional study assesses Medicaid spending associated with citrate-free vs original adalimumab. read more here.
Keywords: estimated medicaid; citrate free; adalimumab; medicaid spending ... See more keywords
Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Rheumatology"
DOI: 10.1007/s10067-020-05199-w
Abstract: Objective SB5 showed comparable efficacy and safety profile in respect to adalimumab originator (ADA) in randomized clinical trials of rheumatoid arthritis (RA) and psoriasis. We aimed to describe the efficacy and safety of SB5 after… read more here.
Keywords: adalimumab; efficacy safety; safety; sb5 ... See more keywords
Adalimumab-induced sarcoidosis-like reaction involving oral cavity in rheumatoid arthritis: a case-based review
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Rheumatology"
DOI: 10.1007/s10067-021-05654-2
Abstract: Drug-induced sarcoidosis-like reaction (DISR) is a condition almost indistinguishable from sarcoidosis, both clinically and microscopically, consisting of granulomatous tissue reaction associated with a specific therapy. Commonly affected sites are the lungs, hilar lymph nodes, and… read more here.
Keywords: induced sarcoidosis; adalimumab; like reaction; sarcoidosis ... See more keywords
Successful treatment of ankylosing spondylitis with alternative and complementary medicine withdrawal of adalimumab treatment.
Sign Up to like & getrecommendations! Published in 2021 at "Complementary therapies in clinical practice"
DOI: 10.1016/j.ctcp.2021.101494
Abstract: BACKGROUND AND PURPOSE Current treatment strategies for ankylosing spondylitis (AS) include adalimumab and other biological drugs. However, treatment failures and side effects are commonly observed. This report documents the successful use of supplements and dietary… read more here.
Keywords: medicine; adalimumab; ankylosing spondylitis; treatment ... See more keywords
Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial
Sign Up to like & getrecommendations! Published in 2021 at "International Immunopharmacology"
DOI: 10.1016/j.intimp.2021.107961
Abstract: Background COVID-19, which is a disease caused by the SARS-CoV-2 virus, has spread around the world since late 2019. Studies have found associations between the rising levels of TNF-α and severe COVID-19 cases. Hence, TNF-α… read more here.
Keywords: randomized controlled; covid cases; adalimumab; controlled trial ... See more keywords
Adalimumab improves cognitive impairment, exerts neuroprotective effects and attenuates neuroinflammation in an Aβ1-40-injected mouse model of Alzheimer's disease.
Sign Up to like & getrecommendations! Published in 2019 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2019.04.054
Abstract: The pathogenesis of Alzheimer's disease (AD) is associated with an increased inflammatory response via activated microglia and astrocytes. In the present study, we investigated whether treatment with the anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody… read more here.
Keywords: alzheimer disease; neuroinflammation injected; treatment; adalimumab ... See more keywords
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2022.2043546
Abstract: Abstract Background Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatment, and lower risks and costs. However, fear for increased… read more here.
Keywords: anti drug; adalimumab; drug; interval prolongation ... See more keywords
Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases.
Sign Up to like & getrecommendations! Published in 2022 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2022.2123703
Abstract: BACKGROUND We aimed to compare the efficacy and safety of the original product (OP) and biosimilar product (BP) of adalimumab in pediatric rheumatic diseases. RESEARCH DESIGN AND METHODS The study group consisted of patients who… read more here.
Keywords: efficacy safety; group; adalimumab; biosimilar adalimumab ... See more keywords
Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2023.2203812
Abstract: BACKGROUND Biosimilar adalimumabs have improved treatment access, but without any clinical advantage, distributors rely on delivery device design-enhancements, support services, and removal of painful excipients to capture market share. Prescribers, however, are often unaware of… read more here.
Keywords: originator versus; adalimumab biosimilars; versus adalimumab; adalimumab ... See more keywords
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Sign Up to like & getrecommendations! Published in 2020 at "Inflammatory Bowel Diseases"
DOI: 10.1093/ibd/izaa078
Abstract: Abstract The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment landscape in Crohn’s disease (CD). The overall therapeutic achievements with TNF inhibitors such as infliximab, adalimumab, and certolizumab pegol paved the… read more here.
Keywords: adalimumab; clinical practice; infliximab; treatment ... See more keywords
Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead181
Abstract: OBJECTIVES To evaluate enthesitis treatment response, including time to resolution and data from multiple enthesitis instruments, in patients with psoriatic arthritis (PsA) treated with secukinumab or adalimumab for 52 weeks. METHODS In this post hoc analysis… read more here.
Keywords: lei sparcc; secukinumab adalimumab; resolution; adalimumab ... See more keywords